These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 31839860)
21. Activated Prothrombin Complex Concentrate versus Plasma for Reversal of Warfarin-Associated Hemorrhage. Rowe AS; Mahbubani PS; Bucklin MH; Clark CT; Hamilton LA Pharmacotherapy; 2016 Nov; 36(11):1132-1137. PubMed ID: 27726162 [TBL] [Abstract][Full Text] [Related]
22. Fixed-dose prothrombin complex concentrate for emergent warfarin reversal among patients with intracranial hemorrhage. Dietrich SK; Mixon MA; Rech MA Am J Emerg Med; 2021 Nov; 49():326-330. PubMed ID: 34224954 [TBL] [Abstract][Full Text] [Related]
23. Activated prothrombin complex concentrate for warfarin reversal in traumatic intracranial hemorrhage. Carothers C; Giancarelli A; Ibrahim J; Hobbs B J Surg Res; 2018 Mar; 223():183-187. PubMed ID: 29433872 [TBL] [Abstract][Full Text] [Related]
24. Modified version of the American College of Cardiology's recommendation for low-dose prothrombin complex concentrate is effective for warfarin reversal. Gilbert BW; Morton L; Huffman JB; Roemer K; Potter A; Cassidy CD; Vasquez DG Am J Emerg Med; 2020 Apr; 38(4):806-809. PubMed ID: 31864879 [TBL] [Abstract][Full Text] [Related]
25. Activated Prothrombin Complex Concentrate Versus 4-Factor Prothrombin Complex Concentrate for Vitamin K-Antagonist Reversal. Rowe AS; Dietrich SK; Phillips JW; Foster KE; Canter JR Crit Care Med; 2018 Jun; 46(6):943-948. PubMed ID: 29498942 [TBL] [Abstract][Full Text] [Related]
26. Evaluation of a Fixed-Dose Regimen of 4-Factor Prothrombin Complex Concentrate for Warfarin Reversal. McMahon C; Halfpap J; Zhao Q; Bienvenida A; Rose AE Ann Pharmacother; 2021 Oct; 55(10):1230-1235. PubMed ID: 33522256 [TBL] [Abstract][Full Text] [Related]
27. Multi-centered evaluation of a novel fixed-dose four-factor prothrombin complex concentrate protocol for warfarin reversal. Dietrich SK; Mixon M; Holowatyj M; Werth JC; Delgado SA; Mascolo NE; Meister ER; Zoucha SM; Trujillo TC Am J Emerg Med; 2020 Oct; 38(10):2096-2100. PubMed ID: 33152586 [TBL] [Abstract][Full Text] [Related]
28. Adjusted versus actual body weight dosing of 4-factor prothrombin complex concentrate in obese patients with warfarin-associated major bleeding. Smetana KS; Ziemba R; May CC; Erdman MJ; Van Matre ET; Jones GM J Thromb Thrombolysis; 2019 Apr; 47(3):369-374. PubMed ID: 30460443 [TBL] [Abstract][Full Text] [Related]
29. Four-factor prothrombin complex concentrate for life-threatening bleeds or emergent surgery: A retrospective evaluation. Sin JH; Berger K; Lesch CA J Crit Care; 2016 Dec; 36():166-172. PubMed ID: 27546767 [TBL] [Abstract][Full Text] [Related]
30. Low-dose compared to manufacturer-recommended dose four-factor prothrombin complex concentrate for acute warfarin reversal. Zemrak W; Manuel F; Smith KE; Rolfe S; Hayes T; Trowbridge RL; Carlone B; Seder D J Thromb Thrombolysis; 2019 Feb; 47(2):263-271. PubMed ID: 30443817 [TBL] [Abstract][Full Text] [Related]
31. Weight-Based Dosing Versus a Fixed-Dose Regimen of 4-Factor Prothrombin Complex Concentrate in Obese Patients Requiring Vitamin K Antagonist Reversal. Elsamadisi P; Cepeda MAG; Yankama T; Wong A; Tran Q; Eche IM Am J Cardiovasc Drugs; 2021 May; 21(3):355-361. PubMed ID: 33150496 [TBL] [Abstract][Full Text] [Related]
32. Optimizing the dose of three-factor prothrombin complex concentrate in traumatic brain injury patients on warfarin therapy. Huynh TK; Costello JL; Rebuck JA Pharmacotherapy; 2014 Mar; 34(3):260-4. PubMed ID: 24338807 [TBL] [Abstract][Full Text] [Related]
33. Comparison of the safety and efficacy between 3-factor and 4-factor prothrombin complex concentrates for the reversal of warfarin. Kuroski JE; Young S Am J Emerg Med; 2017 Jun; 35(6):871-874. PubMed ID: 28161220 [TBL] [Abstract][Full Text] [Related]
34. Impact of Obesity on Warfarin Reversal With Fixed-Dose Factor VIII Inhibitor Bypassing Activity (aPCC). McKinney AL; Dailey LM; McMillen JC; Rowe AS Ann Pharmacother; 2021 Jul; 55(7):856-862. PubMed ID: 33094635 [TBL] [Abstract][Full Text] [Related]
35. Rapid Warfarin reversal in the setting of intracranial hemorrhage: a comparison of plasma, recombinant activated factor VII, and prothrombin complex concentrate. Woo CH; Patel N; Conell C; Rao VA; Faigeles BS; Patel MC; Pombra J; Akins PT; Axelrod YK; Ge IY; Sheridan WF; Flint AC World Neurosurg; 2014 Jan; 81(1):110-5. PubMed ID: 23220122 [TBL] [Abstract][Full Text] [Related]
36. Prothrombin complex concentrate versus standard therapies for INR reversal in trauma patients receiving warfarin. Chapman SA; Irwin ED; Beal AL; Kulinski NM; Hutson KE; Thorson MA Ann Pharmacother; 2011 Jul; 45(7-8):869-75. PubMed ID: 21775690 [TBL] [Abstract][Full Text] [Related]
37. Thromboembolic risks of recombinant factor VIIa Use in warfarin-associated intracranial hemorrhage: a case-control study. H-Y CS; Xuemei C; G KR; M BL; V HG; A SF; K FS BMC Neurol; 2012 Dec; 12():158. PubMed ID: 23241423 [TBL] [Abstract][Full Text] [Related]
38. Prothrombin complex concentrate accelerates international normalized ratio reversal and diminishes the extension of intracranial hemorrhage in geriatric trauma patients. Edavettal M; Rogers A; Rogers F; Horst M; Leng W Am Surg; 2014 Apr; 80(4):372-6. PubMed ID: 24887668 [TBL] [Abstract][Full Text] [Related]
39. Comparison of 3-Factor Prothrombin Complex Concentrate and Low-Dose Recombinant Factor VIIa for Warfarin Reversal. Chapman SA; Irwin ED; Abou-Karam NM; Rupnow NM; Hutson KE; Vespa J; Roach RM World J Emerg Surg; 2014; 9():27. PubMed ID: 24731393 [TBL] [Abstract][Full Text] [Related]
40. Impact of a Pharmacist-Driven Prothrombin Complex Concentrate Protocol on Time to Administration in Patients with Warfarin-associated Intracranial Hemorrhage. Corio JL; Sin JH; Hayes BD; Goldstein JN; Fuh L West J Emerg Med; 2018 Sep; 19(5):849-854. PubMed ID: 30202498 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]